Profil
Markus F.
Renschler is President & Director at Cyteir Therapeutics, Inc. since 2018.
Former roles include Senior Vice President & Global Head-Hematology at Celgene Corp., Senior VP-Oncology Clinical Development at Pharmacyclics LLC from 1996 to 2007, Vice President-Clinical Development at Pharmion Corp.
from 2007 to 2008, Associate Professor at Stanford University, and Chief Medical Officer & Senior Vice President at Celgene Cellular Therapeutics from 2008 to 2017.
Education includes a doctorate from Stanford University and an undergraduate degree from Princeton University.
Aktive Positionen von Markus Renschler
| Unternehmen | Position | Beginn |
|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Präsident | 01.01.2018 |
Ehemalige bekannte Positionen von Markus Renschler
| Unternehmen | Position | Ende |
|---|---|---|
Celgene Cellular Therapeutics
Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Develops human pharmaceuticals | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2017 |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.01.2015 |
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of products for the treatment of hematology & oncology patients | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2008 |
| PHARMACYCLICS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 28.12.2007 |
| CELGENE | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Markus Renschler
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 7 |
|---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Develops cancer and immunology drugs | Health Technology |
Pharmacyclics LLC
Pharmacyclics LLC Pharmaceuticals: MajorHealth Technology Manufactures drugs intended to treat cancer and atherosclerosis | Health Technology |
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Engages in the development and commercialization of products for the treatment of hematology & oncology patients | Health Technology |
Stanford University
Stanford University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Princeton University
Princeton University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage oncology company | Health Technology |
Celgene Cellular Therapeutics
Celgene Cellular Therapeutics Pharmaceuticals: MajorHealth Technology Develops human pharmaceuticals | Health Technology |
















